Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
Retrieved on:
Thursday, November 9, 2023
EGFR, Research, NSCLC, Fatigue, Epithelioid hemangioendothelioma, TEAD, Diarrhea, Physician, Hippopotamus, Weight gain, Meningioma, Liver, Quarter, Wind, Additive effect, Nausea, NF2, Quality of life, Growth, Disease, Caregiver, Clinical trial, Neoplasm, TEAD1, Biology, DLT, Cancer, Partnership, Collaboration, Mesothelioma, Liver failure, Nephrotoxicity, Blood, Pain, Patient, VGLL4, TAZ, EHE, Therapeutic index, Proteinuria, Pharmaceutical industry, Vaccine, Cryptocurrency, Pionýr
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
Key Points:
- The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
- “This early look at the IK-930 dose escalation data strongly supports our differentiated approach to targeting the Hippo pathway.
- Importantly, following the target biology and initially focusing on EHE has allowed us to observe clinical activity of IK-930 early in our dose escalation.
- Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023.